iBio rises as obesity drug gets nod for human trial in Australia

iBio

08/04/2026 16:16

Updates

** Shares of iBio IBIO.O rise nearly 5% to $2.21

** Biotech firm says Australian regulators have cleared first human study of its experimental obesity drug IBIO-600

** Drug targets obesity and aims to preserve muscle while people lose weight - IBIO

** Says IBIO-600 is designed to be used alongside GLP-1 weight-loss drugs, which can cause muscle loss

** Adds that early-stage study will test safety and how the drug behaves in overweight and obese adults

** Animal studies showed gains in lean muscle and reductions in fat; drug could be dosed just a few times a year - IBIO

** Including session's move, stock up about 15% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))